Construction of artificial virus-like particles exposing HIV epitopes, and the study of their immunogenic properties

Vaccine

Volumn 21, Issue 5-6, 2003, Pages 386-392

  Karpenko, Larisa I ^a   Lebedev, Leonid R ^a   Ignatyev, George M ^a   Agafonov, Alexander P ^a   Poryvaeva, Vera A ^a   Pronyaeva, Tatiana R ^a   Ryabchikova, Elena I ^a   Pokrovsky, Andrei G ^a   Ilyichev, Alexander A ^a  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

Author keywords

Artificial immunogens; Epitopes; HIV; Virus like particles

Indexed keywords

ANTIGEN; DEXTRAN; GLUTATHIONE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; RECOMBINANT VACCINE; RNA; SPERMIDINE;

ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS PARTICLE; YEAST;

AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CELL DIVISION; CHEMISTRY, PHYSICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENETIC VECTORS; HIV-1; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; NEUTRALIZATION TESTS; POLYSACCHARIDES; RECOMBINANT PROTEINS; RNA, DOUBLE-STRANDED; SACCHAROMYCES CEREVISIAE; SPLEEN; T-LYMPHOCYTES;

EID: 0037449509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00406-1     Document Type: Article

References (28)

1. Velin D., Hopkins S., Kraehenbuhl J.P. Delivery systems and adjuvants for vaccination against HIV. Pathobiology. 66:1998;170-175.
2. Cohen J. Merck reemerges with a bold AIDS vaccine effort. Science. 292:2001;24-25.
3. Berzofsky J.A. Design of engineered vaccines for systemic and mucosal immunity to HIV. Pathol. Biol. 49:2001;466-467.
4. Veljkovic V., Metlas R., Kohler H., Urnovitz H.B., Prljic J., Veljkovic N.et al. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. Vaccine. 19:2001;1855-1862.
5. Klein M. Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. Vaccine. 19:2001;2210-2215.
6. Hilleman M.R. A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS. Vaccine. 16:1998;778-793.
7. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 57:1993;183-289.
8. Letvin NL. Progress in the development of an HIV-1 vaccine. Science 1998;280:5371, 1875-80.
9. Eroshkin A.M., Zhilkin P.A., Shamin V.V. Design of four-helix protein - a possible vaccine against human immunodeficiency virus (HIV-1). Mol. Biol. (Moscow). 27:1993;538-551.
10. Loktev V.B., Ilyichev A.A., Eroshkin A.M., Karpenko L.I., Pokrovsky A.G., Svyatchenko V.A.et al. Design of immunogens as components of a new generation of molecular vaccines. J. Biotechnol. 44:1996;129-137.
11. Morris C.B., Thanawastien A., Sullivan D.E., Clements J.D. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response. Vaccine. 20:2001;12-15.
12. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimisation of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 19:2001;4652-4660.
13. Eroshkin A.M., Karginova E.A., Gileva I.P., Lomakin A.S., Lebedev L.R., Kamyinina T.P.et al. Design of four-helical protein as a candidate for HIV vaccine. Protein Eng. 8:1995;167-173.
14. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor; 1989.
15. Duzhak A.B., Kostomakha A.N., Lobova N.N., Podgornyi V.F., Nosik N.N. Natural interferon inducers: double-stranded RNA of killer plasmids of Saccharomyces cerevisiae. Antibiot. Med. Biotechnol. 30:1985;19-21.
16. Ridostin for injection. Berdsk, Russia: Pharmaceutical Article, VFS 42-2457-94.
17. Albert J., Abrahamsson B., Nagy K.et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS Res. Hum. Retroviruses. 4:1990;107-112.
18. Sawyer L.A., Klatzenstein D.A., Hendry R.M.et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses. 6:1990;341-356.
19. Wagner R., Shao Y., Wolf H. Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Vaccine. 17:1999;1706-1710.
20. Pumpens P., Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology. 44:2001;98-114.
21. Heinz F.X., Allison S.L., Stiasny K., Schalich J., Holzmann H., Mandl C.W.et al. Recombinant and virion-derived soluble and particulated immunogens for vaccination against tick-borne encephalitis. Vaccine. 18:1995;1636-1642.
22. von Brunn A., Brand M., Reichhuber C., Morys-Wortmann C., Deinhardt F., Schooled F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine. 11:1993;817-824.
23. Isaguliants M.G., Nordlund S., Sallberg M., Smirnov V.D., Ruden U., Wahren B. HIV-1 epitopes exposed by hybrid hepatitis B core particles affect proliferation of peripheral blood mononuclear cells from HIV-1 positive donors. Immunol. Lett. 52:1996;37-44.
24. Moore A., McGuirk P., Adams S., Jones W.C., McGee J.P., O'Hagan D.T.et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine. 13:1995;741-749.
25. Kang C.Y., Luo L., Wainberg M.A., Li Y. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol. Chem. 380:1999;353-364.
26. Haglund K., Forman J., Krausslich H.G., Rose J.K. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology. 268:2000;112-121.
27. Marusic C., Rizza P., Lattanzi L., Mancini C., Spada M., Belardelli F.et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 75:2001;8434-8439.
28. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55 gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retrovir. 16:2000;273-282.